A grant of $3.4 million has been granted as a funding for developing therapies for diseases like Parkinson’s, motor neuron disease, and other neurological disorders. The project will start this month and the Biomedical Catalyst (BMC) award will support it for two years. NGR is supporting to advance in mitochondrial biology to develop effective therapies for neurodegenerative disorders. The mPTP in brain cells will be hindered by the company, which has been seen as a neuroprotective agent in many preclinical studies of Parkinson’s and MND models.
Read More from Pharmaceutical Technology
English